Home › Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014
 

Keywords :   


Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014

2014-09-02 14:30:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the companys investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 30. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin Holko 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data present types studies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09UK economy grew less than thought in spring
30.09House price growth at near two-year high
30.09Traditional steelmaking ends in Port Talbot
30.09Eastern North Pacific Tropical Weather Outlook
30.09Atlantic Tropical Weather Outlook
30.09Eastern North Pacific Tropical Weather Outlook
30.09California governor blocks landmark AI safety bill
30.09Tropical Depression Joyce Forecast Advisory Number 11
More »